Ceapro Inc. Presents Its PGX Technology at the 15th European Meeting on Supercritical Fluids
EDMONTON, ALBERTA -- (Marketwired) -- 05/09/16 -- Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that it presented this morning its PGX Technology at the 15th European Meeting on Supercritical Fluids being held in Essen, Germany.
The oral presentation entitled, "PGX Technology: An Enabling Technology for Generating Biopolymer Fibrils, Particles Aerogels and Nano-Composites," was presented by Bernhard Seifried, Ph.D., Senior Research Scientist at Ceapro and co-inventor of the PGX Technology, during the session: Materials - Organic materials, polymers and composites, chaired by Irina Smirnova.
Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, commented, "We are honored to have been invited for a podium presentation at such a prestigious scientific meeting."
"Over the course of the past 12-18 months, we have begun to witness how our unique and disruptive enabling PGX technology will play a key role in taking Ceapro to its next stage of growth. The data presented by Dr. Seifried supports the broad utility of our PGX Technology and its ability to enable us to expand our business model into highly attractive, well established and growing industries," Mr. Gagnon added.
About Pressurized Gas eXpanded Liquid Technology (PGX)
PGX is a unique and disruptive technology with several key advantages over conventional drying and purification technologies that can be used to process biopolymers into high-value, nano-sized polymer structures and novel bio-nanocomposites. PGX is ideally suited for processing challenging high-molecular-weight, water-soluble biopolymers. It has the ability to make ultra-light, highly porous polymer structures on a continuous basis, which is not possible using today's conventional technologies. PGX was co-invented by Ceapro researcher Dr. Bernhard Seifried and University of Alberta professor, Dr. Feral Temelli.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at www.ceapro.com.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): 908-938-1475
Source: Ceapro Inc.
Released May 9, 2016